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Abstract 1 
Breast cancer (BC) is one of the leading causes of cancer-related death among women 2 
worldwide, and claudin-low breast cancer (CLBC) is a subtype of BC that remains poorly 3 
described. This study aimed to identify upregulated genes and significant pathways involved in 4 
CLBC. The SUM159 cell line is derived from human CLBC tissue; the GSE50697 dataset 5 
contains three replicates of SUM159 cells treated with pBabe puro miR-203 and three replicates 6 
of control SUM159 cells (pBabe puro). The data were normalized and upregulated, and 7 
downregulated genes were identified based on the logFC values. Gene Ontology (GO) and 8 
pathway analysis identified the most significant pathways and genes involved in CLBC 9 
pathogenesis. A total of 156 significant genes were identified (69 upregulated genes and 64 10 
downregulated genes). From the pathway analysis, the senescence-associated secretory 11 
phenotype, which involves the CXCL8, IL1A, and IL6 genes, was found to be mapped through 12 
more than one pathway (WikiPathways and Reactome). From the refined GO analysis, the IL-13 13 
signaling pathway was identified; this pathway includes the IL6, CXCL8, VEGF-C, NRG1, and 14 
EREG genes, which were mapped as hub genes in several pathogenesis pathways. From the 15 
survival analysis, high levels of IL6, CXCL8, and EREG were related to high survival rates, and 16 
low levels of VEGFC and NRG1 were related to high survival rates. The IL6 and CXCL8 genes 17 
were the most significant and the most highly represented in the GO and refined GO analyses. 18 
This study might provide a potential biomarker for the treatment of CLBC. 19 
Keywords: Breast cancer, Microarray, Claudin-low breast cancer, Biomarkers, Functional 20 
enrichment analysis, Differential gene expression 21 
 22 
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Introduction 1 
Cancer is a broad set of diseases wherein cells divide, grow, and invade other parts of the body 2 
abnormally and without control. Classification of cancer depends primarily on the cell type and 3 
origin of the tumor; cancer can be classified as carcinoma, sarcoma, or lymphoma based on 4 
whether the tumor is derived from epithelial cells, connective tissue, or lymph nodes, 5 
respectively. Cancers with the highest incidence are lung, breast, stomach, prostate, colorectal, 6 
and uterine cancer (Rahman and Zayed 2018; Sidenna et al. 2019; Siegel, Miller, and Jemal 7 
2019; Thirumal Kumar et al. 2019; Younes and Zayed 2018). Among all the different types of 8 
cancers identified to date, breast cancer (BC) accounts for 14% of cancers in women and is the 9 
second most commonly occurring cancer worldwide (Ferlay et al. 2013; Thirumal Kumar and 10 
George Priya Doss 2016b, 2017). BC is thought to be a genetic disorder that is caused by 11 
mutations in different genes that control metabolic pathways and the cell cycle (De and 12 
Kuppusamy 2019; Sudhakar et al. 2016). Although the majority of patients present with 13 
symptoms of BC, which includes a lump in the breast, a distortion in breast shape, dimpling of 14 
the skin of the breast, fluid impending from the nipple, a newly inverted nipple or a red or scaly 15 
patch of skin of the breast, approximately 40% cases are diagnosed by the NHS breast screening 16 
program when they are asymptomatic (Sibbering and Courtney 2016). This UK-based screening 17 
method, according to the evidence provided by Threlfall et al reduces BC mortality (Threlfall, 18 
Collins, and Woodman 2003). 19 
Family history and genetics are significant risk factors for the development of BC (Gazalla Ayub 20 
et al. 2014; Neamatzadeh, Shiryazdi, and Kalantar 2015). Approximately 3% to 10% of BCs and 21 
approximately 30% of all early-onset BCs are caused by hereditary factors (Calderón-22 
Garcidueñas et al. n.d.). Germline mutations in BC genes (BRCA1 and BRCA2) are considered 23 
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to be the primary gene changes associated with breast and ovarian cancers (Kwong et al. 2011; 1 
Mehrgou and Akouchekian 2016). BRCA1 is positioned at chromosome 17q, and BRCA2 is 2 
located at chromosome 13q. These two genes are tumor suppressor genes, and mutations in these 3 
genes lead to approximately 30% of all breast and ovarian cancers (Martínez-Ferrandis et al. 4 
2003; Pohlreich et al. 2005). A precise human gene locus comprising 15 kallikrein genes on 5 
chromosome 19q13.4 is recognized as being the leading continuous gene group of serine 6 
proteases in the human genome. Kallikreins are seen in epithelial and endocrine tissues and, 7 
therefore, are probable serum biomarkers in ovarian, breast, and prostate cancers (Coticchia et al. 8 
2009). 9 
In addition to these common cancer types, there is a cancer type known as claudin-low breast 10 
cancer (CLBC), which is a molecular subtype of BC that is associated with poor prognosis and 11 
has no specific treatment so far. Thus, treatments and diagnostic biomarkers for this type of BC 12 
are needed. Microarray analysis is a recent technique that is widely used in the analysis of patient 13 
samples and the identification of disease biomarkers. This technique is most commonly used in 14 
the treatment of cancer and bacterial infections (Kaliyappan et al. 2012). A recent study by Xie et 15 
al. (2019) evaluated three different BC cell lines from different GEO datasets to study the 16 
functions of the intersectin-1 (ITSN1) gene in BC. The dataset included the GEO dataset with ID 17 
GSE50697 (Xie et al. 2019). This dataset contains samples from CLBC tissue treated with pBabe 18 
puro miR-203. The microarray data of the CLBC cell line expressing microRNA-203 were used 19 
for this study (Taube et al. 2013). Epithelial-Mesenchymal Transition (EMT) facilitates the 20 
migration and invasion of cancer cells and increases the ability of cancer cells to grow in a 21 
secondary site by promoting their survival in the blood circulation (Kalluri and Weinberg 2009; 22 
Mani et al. 2008; O'Regan et al. 2017; Polyak and Weinberg 2009; Thiery 2002). MiR-200 23 
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targets the transcription factors that induce EMT: Zeb1 and Zeb2 (Bracken et al. 2008; Gregory 1 
et al. 2008; Park et al. 2008). The activity of Zeb1 and Zeb2 is suppressed by histone 2 
modification and DNA methylation, which then promotes EMT at the initial stage of 3 
carcinogenesis (Neves et al. 2010; Tellez et al. 2011; Vrba et al. 2010). The expression of miR-4 
203 in mesenchymal cells reduces the migratory and invasive capacities of cells in vitro and 5 
results in tumor initiation and metastasis in vivo (Taube et al. 2013). Expression of miR-203 6 
reduces B-catenin levels by enhancing the expression of DKK1, which plays a significant role as 7 
an inhibitor of Wnt signaling. It affects the stemness of adjacent cells (Li et al. 2010). Increased 8 
levels of miR-203 expression may result in the inhibition of metastasis. This study aimed to use a 9 
computational analysis pipeline to identify the significant biological pathways and genes 10 
involved in CLBC, thereby identifying biomarkers for the treatment of CLBC. 11 
 12 
Materials and Methods 13 
Dataset 14 
The microarray dataset was retrieved from the GEO database with GEO accession number 15 
GSE50697 (Clough and Barrett 2016; Taube et al. 2013). This dataset contains six samples in 16 
CEL format with accession numbers GSM1226581, GSM1226582, GSM1226583, 17 
GSM1226584, GSM1226585, and GSM1226586 corresponding to SUM159 control reps 1, 2, 3 18 
and SUM159 miR-203 reps 1, 2, 3, respectively. 19 
Data normalization and quality control 20 
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Chipster, a user-friendly software used for analyzing high-throughput data such as NGS and 1 
microarrays, was used in our study to analyze the CLBC dataset (Kallio et al. 2011). The 2 
normalization of the CEL files estimates the expression and call values for the genes. The Robust 3 
Multichip Averaging (RMA) normalization method with original Affymetrix annotations was 4 
used for normalization. The Quality Control (QC) stat, RNA degradation, and spike-in 5 
performance plots were obtained as the output. Further, quality control was assessed using the 6 
Affymetrix primary method. 7 
Preprocessing of the normalized data 8 
The normalized files were classified into two groups using the Phenodata editor of the Chipster 9 
package (https://chipster.csc.fi/). The control samples were grouped under number 1, the samples 10 
treated with pBabe puro miR-203 were grouped under number 2, and a standard deviation value 11 
of 3 SDs (99.7%) was set as the base value to filter the significant genes. 12 
Statistical analysis and annotations 13 
Since the retrieved sample dataset contains two groups, a two-group statistical test was 14 
performed with the default empirical Bayes test and p-value adjusted with the Benjamini-15 
Hochberg correction (BH) method (Benjamini and Hochberg 1995). The p-value threshold for 16 
significance was set to 0.05. Further, the annotation was performed using the Affymetrix gene 17 
list. 18 
Clustering and pathway enrichment analysis of DEGs 19 
Gene clustering was performed using the Pearson distance with the average tree method (VII. 20 
Note on regression and inheritance in the case of two parents 1895). A total of 1000 iterations 21 
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were generated to identify the most appropriate clusters. The pathways were identified using the 1 
gene set test against the KEGG pathway with a minimum pathway size of 5 and a p-value of 0.05 2 
(Kanehisa 2000). The multiple testing correlation was analyzed using the BH method. The 3 
hypergeometric test for GO was performed to classify genes based on various ontologies, such as 4 
biological process, molecular function, and cellular component, with a minimum of five 5 
populations and overrepresentation against the AmiGO 2 database. Finally, the hypergeometric 6 
test for ConsensusPathDB (http://cpdb.molgen.mpg.de/) was analyzed with a p-value threshold 7 
of 0.05 with a gene symbol as an identifier (Kamburov et al. 2011). 8 
Fold change calculation & PPI network construction 9 
The fold change between the two groups was calculated as the geometric mean with a scale of 10 
log2. The Cytoscape standalone package was used to build the interactions between the 11 
identified significant genes (Shannon et al. 2003). The 'stringApp' plugin of Cytoscape was used 12 
to retrieve the interacting genes with the identified significant genes with a confidence cutoff of 13 
0.40. This plugin extracts the pool of interacting genes based on the data from the online 14 
STRING database. 15 
Refined GeneGo Analysis 16 
The significant DEGs were further examined in MetaCore, Cortellis solution software. GeneGo 17 
empowers the quick and easy analysis of protein networks, metabolic pathways, and maps for the 18 
list of genes/proteins (MetaCore Login|Clarivate Analytics). The pathway maps tool was used to 19 
identify the enriched pathways involving DEGs in terms of the hypergeometric distribution, and 20 
the p-values were analyzed by using the default database. The graphical depictions of the 21 
interactions were generated based on a significant p-value < 0.05. 22 
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Survival and Expression DIY analysis 1 
The survival and expression DIY analysis were performed using the online GEPIA2 server 2 
(http://gepia2.cancer-pku.cn/) with the BC dataset selected for the analysis. For survival analysis, 3 
the samples were divided into high and low expression groups according to the 50% cutoff value. 4 
The confidence interval was maintained at 95%. For the box plot analysis, the |Log2FC| cutoff 5 
was set to 1, and the p-value cutoff was set to 0.01. 6 
Results 7 
Data Normalization and Quality Control 8 
Data normalization and quality control were performed using the robust multichip averaging 9 
(RMA) method to obtain the QC stat, RNA degradation, and spike-in performance plots. The QC 10 
data aids in the understanding of the number of probesets in the present flag and backgrounds in 11 
the chip. The percent in probesets in the microarray001.cel, microarray002.cel, 12 
microarray003.cel, microarray004.cel, microarray005.cel, and microarray006.cel chips were 13 
41.54%, 42.11%, 40.82, 39.4%, 39.57%, and 41.36%, respectively. Additionally, the average 14 
background on the chip was found to be 46.99, 49.29, 49.97, 50.88, 53.95, and 53.67, 15 
respectively. The GAPDH3/GAPDH5 scaling factor/ratios were found to be within 1.25-fold, as 16 
observed by the blue color (Supplementary Figure 1). Further, RNA degradation plots and spike-17 
in performance plots were generated and showed that the slopes and profiles were similar and 18 
stable across the plot and provided confidence that the samples were suitable for further analysis 19 
(Supplementary Figure 2A-B). 20 
Preprocessing the normalized data and fold change (FC) calculation 21 
9 
 
The samples were mapped into control and disease using the phenodata editor package, and 1 
preprocessing was initiated with a standard deviation of 0.997, which is 99.7% significance or 3 2 
SDs. The filtration process demonstrated 165 genes that satisfied this condition. The symbols of 3 
17 genes were not identified during the process; hence, they are noted as 'NA' in the description 4 
(Supplementary Table 1). As there were two groups (control and miR-203), two groups' tests 5 
were performed with the BH, p-value adjustment method and p-value threshold of 0.05 with 6 
normalized gene data and phenodata as input. From the statistical analysis, 156 genes were found 7 
to be significant, out of which 17 lacked gene annotation (Supplementary Table 2). The gene 8 
expression heat map is shown in Supplementary Figure 3. 9 
Further, hierarchical clustering was analyzed with these genes with the Pearson distance average 10 
tree method with 1000 replicates. The obtained hierarchical clustering is shown in 11 
Supplementary Figure 4. The fold change calculation was calculated between the two groups 12 
with the geometric mean and scale of log2 for the 156 DEGs. The genes with FC values above 1 13 
were identified to be upregulated, and the genes with FC values below -1 were identified to be 14 
downregulated. From the FC values, 69 genes were found to be upregulated, 64 genes were 15 
found to be downregulated, and 17 unidentified genes were excluded from the study 16 
(Supplementary Table 3). The volcano plot was generated with the corresponding data: the 17 
upregulated genes are mapped in red, and the downregulated genes are mapped in green. In 18 
contrast, the genes that did not change are mapped in black (Supplementary Figure 5). 19 
PPI network construction and pathway analysis 20 
The interacting network of upregulated and downregulated genes is shown using Cytoscape 21 
software, and the data retrieved from the STRING database are provided in Supplementary Table 22 
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4; 69 nodes and 126 edges were obtained as the result of the interaction (Figure 1). The network 1 
of interacting upregulated genes is shown in Figure 2. Further, the pathways and gene list were 2 
analyzed among the groups with a p-value threshold of 0.05 and BH multiple testing correction 3 
methods. The analysis of upregulated genes revealed involvement in 211 pathways, of which 4 
toxoplasmosis, lysine degradation, glycerolipid metabolism, pathways in cancer, and mTOR 5 
signaling ranked highest, with networks of 5145, 310, 561, 5200, and 4150 genes, respectively 6 
(Supplementary Table 5). A positive and negative correlation between the dysregulated genes 7 
and the top 5 pathways are shown in Supplementary Figure 6A-4E. Further, the gene annotation 8 
was performed using the Affymetrix gene list parameter, including Probe, Symbol, Description, 9 
Chromosome, Chromosome, Location, GenBank, Gene, Cytoband, UniGene, PubMed, Gene 10 
Ontology, and Pathway for the 156 significant genes. The detailed data with cross-references 11 
against NCBI and KEGG database hyperlinks are provided in Supplementary File 1. 12 
Pathway enrichment analysis of DEGs 13 
Hypergeometric Gene Ontology (GO) was performed to identify the various processes, such as 14 
biological process, molecular function, and cellular component. They yielded 165, 6, and 7 GO 15 
terms for biological process, molecular function, and cellular component, respectively. 16 
(Supplementary Table 6). The hypergeometric test for ConsensusPathDB was performed against 17 
ConsensusPathDB (http://cpdb.molgen.mpg.de/) with humans as a reference to map the genes to 18 
the respective pathways. This analysis identified 193 different pathways, and the respective 19 
genes were mapped to the identified pathways. Senescence-associated secretory phenotype 20 
(SASP) was associated with CXCL8, IL1A, and IL6 genes and was mapped through 21 
WikiPathways as well as through Reactome predictions (Supplementary Table 7). 22 
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Refined GeneGo Analysis 1 
Refined GeneGo analysis was performed using MetaCore software to identify the top 10 2 
pathway maps, GO processes, process networks, and diseases (by biomarkers). From the 3 
pathway analysis, immune response IL-13 signaling via JAK-STAT, G protein-coupled receptor 4 
signaling in lung cancer, and cell adhesion ECM remodeling were found to be ranked in the top 3 5 
in the analysis. Second-messenger-mediated signaling, anatomical structure development, and 6 
multicellular development were found to be the top 3 ranked GO processes. Inflammation-7 
related IL-13 signaling, cell adhesion cell-matrix interaction, and inflammation histamine 8 
interactions were found to be the top 3 in terms of process network. Based on disease 9 
biomarkers, carcinoma, adenocarcinoma, and colonic diseases were ranked in the top 3. The top 10 
10 list of each analysis is provided in Figure 3A-D. The detailed list of genes involved in 11 
pathway maps, GO processes, process networks, and diseases (by biomarkers) are given in 12 
Tables 1-3 and Supplementary Table 8. The top 3 pathways (immune response IL-13 signaling 13 
via JAK-STAT, G protein-coupled receptor signaling in lung cancer, and cell adhesion ECM 14 
remodeling) with a top-scored map (map with the lowest p-value) based on the enrichment 15 
distribution sorted by 'statistically significant maps' are shown in Figure 4A-C. Finally, the 16 
analyze networks algorithm was employed with the default settings to prioritize the networks 17 
based on the number of fragments of canonical pathways in the network. From the analysis, three 18 
significant networks and their respective processes were identified. The major network included 19 
IL8, which is in the regulation of cell proliferation (90.0%); IL6, which is involved in the 20 
positive regulation of intracellular signal transduction (72.0%); VEGFC, which is involved in the 21 
positive regulation of protein metabolic processes (80.0%); NRG1 (neuregulin 1), which is 22 
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involved in the positive regulation of multicellular organismal processes (82.0%); and EREG 1 
(epiregulin), which is involved in response to hormone (74.0%) functions (Table 4). 2 
Survival and Expression DIY analysis 3 
From the overall survival analysis, it was found that the hazard ratios of the identified significant 4 
genes IL6, CXCL8, VEGF-C, NRG1, and EREG were 0.93, 0.92, 1.1, 0.88, and 0.75, 5 
respectively. Further, the box plot showed considerable changes in gene expression. The IL6 and 6 
NRG1 genes showed a higher significance than the other three genes (Figure 5A-J). A separate 7 
analysis was performed on the four hub genes. The interrelations between the hub genes 8 
identified from the pathways are shown in Figure 6. 9 
 10 
Discussion 11 
This work investigated the gene expression of the SUM159 CLBC cell line expressing 12 
microRNA-203. The study contained six samples: three control samples and three samples 13 
treated with miR-203. The samples were normalized using RMA, and the quality of the samples 14 
was analyzed with the Affymetrix basics tool embedded within Chipster. QC analysis plays a 15 
crucial role in any scientific work that generates huge data. This analysis aids in the 16 
understanding of the quality of a microarray experiment and, in particular, helps to identify 17 
outlier samples, thus revealing highly sensitive data for analysis (Freue et al. 2007; Kauffmann 18 
and Huber 2010; Shieh and Hung 2009). Our QC analysis revealed that the samples were highly 19 
sensitive and appropriate for further analysis (Supplementary Figure 2A and 2B). 20 
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The genes were filtered using the criteria of 99.7% significance, and 165 genes were found to 1 
satisfy the significance criteria. The symbols of 17 genes were not identified during the process 2 
(Supplementary Table 2). From the analysis of genes with a logFC value of 2, 69 genes and 64 3 
genes were found to be upregulated and downregulated, respectively (Supplementary Table 3). 4 
The entire list of 165 genes was subjected to interaction analysis using the STRING database, 5 
and the interactions were visualized using Cytoscape. In total, 69 nodes and 126 edges were 6 
identified to be involved in the interactions (Supplementary Table 4 & Figure 1). To identify the 7 
interactions of genes that are involved in the upregulation, a separate plot was generated (Figure 8 
2). These upregulated genes were found to play a significant role in 211 different pathways. Of 9 
those, toxoplasmosis, lysine degradation, glycerolipid metabolism, pathways in cancer, and 10 
mTOR signaling were found to rank as the most significant (Supplementary Table 5 and 11 
Supplementary Figure 6A-E). Interestingly, all these pathways were found to play a significant 12 
role in BC in previous literature (Chen et al. 2018; Hynes and Boulay 2006; Kalantari et al. 13 
2017; Luo et al. 2017). Further gene annotation was processed using the Affymetrix gene list 14 
parameters. The entire annotated list with hyperlinks is shown in Supplementary File 1. The 15 
hypergeometric test for ConsensusPathDB was performed against the ConsensusPathDB 16 
database with humans as a reference to map the genes to respective pathways. From the analysis, 17 
193 different pathways and the corresponding genes were mapped accordingly. Biocarta, 18 
EHMN, INOH, KEGG, PharmGKM, PID, Reactome, Signalink, SMPDB, and WikiPathways 19 
were employed to identify the pathways to correlate the genes. The senescence-associated 20 
secretory phenotype (SASP) pathway, which involves the CXCL8, IL1A, and IL6 genes, was 21 
mapped through WikiPathways as well as through Reactome (Supplementary Table 7). To 22 
increase the confidence of the above findings, a refined GeneGo analysis was performed to 23 
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identify the top pathway maps, GO processes, process networks, and diseases (by biomarkers). 1 
Immune response IL-13 signaling via JAK-STAT, G protein-coupled receptor signaling in lung 2 
cancer, and cell adhesion ECM remodeling were found to be the top pathways, and the 3 
interactions of these pathways are shown in Figures 3 and 4. Similar to the pathway maps, the 4 
IL-13 signaling pathway was also found to be top-ranked in the process networks, signifying that 5 
the pathway IL-13 signaling pathway could be the more significant pathway in the disease 6 
(Figure 3A-D). This association of interleukin with BC was reported in several earlier research 7 
works, which supported our findings (Cao et al. 2016; DeNardo et al. 2009; Fasoulakis et al. 8 
2018). 9 
The analyze networks algorithm was employed to identify the major networks and genes 10 
involved in the pathway. From the analysis, three major networks and their respective processes 11 
were identified. This result was again found to agree with our earlier findings, where the major 12 
genes among the main networks were found to be IL-8 (CXCL8), which is involved in the 13 
regulation of cell proliferation (90.0%); IL-6, which is involved in the positive regulation of 14 
intracellular signal transduction (72.0%); VEGFC, which is involved in the positive regulation of 15 
protein metabolic processes (80.0%); neuregulin 1, which involved in the positive regulation of 16 
multicellular organismal processes (82.0%); and epiregulin, which is involved in response to 17 
hormone (74.0%) functions (Table 4). IL-8 and IL-6 were previously identified by two different 18 
pathway identifiers (WikiPathways and Reactome) to be involved in the senescence-associated 19 
secretory phenotype (SASP). SASP biomarkers are well-studied tumor suppressors in cancers, 20 
including BC (Campisi 2001; Coppé et al. 2008; Perrott et al. 2017). In particular, Coppé et al., 21 
2008 stressed the involvement of IL-6 and IL-8 in the involvement of tumor suppressor actions, 22 
which supports our findings. There are also suitable previous studies that support the role of our 23 
15 
 
identified genes (VEGF-C, NRG1, and EREG) in the involvement of BC (Farooqui et al. 2015; 1 
Jeong et al. 2014; Skobe et al. 2001). The survival analysis revealed that high levels of IL6, 2 
CXCL8, and EREG were associated with high survival rates; in contrast, low levels of VEGFC 3 
and NRG1 were associated with high survival rates. The IL6 and NRG1 genes were expressed at 4 
significantly higher levels than the other three genes (Figure 5). Finally, correlation analysis 5 
between the identified hub genes (IL6, CXCL8, VEGF-C, NRG1, and EREG) was performed 6 
using the STRING bioinformatics tool. The association between these genes was mainly derived 7 
from text mining and coexpression analysis involving the EREG, CXCL8, IL6, and VEGF-C 8 
genes. The identified hub genes were shown to be associated with various signaling pathways by 9 
interacting with each other (Figure 6). The results depict that CXCL8 was found to be involved in 10 
the regulation of signaling receptor activity biological process (GO), while VEGF-C was 11 
involved in the regulation of signaling receptor activity and positive regulation of peptidyl-12 
tyrosine phosphorylation biological processes (GO). In addition, from the UniProt Keywords 13 
search, VEGF-C was also found to be involved in mitogen and angiogenesis. The gene IL-6 was 14 
shown to be involved in the positive regulation of peptidyl-tyrosine phosphorylation and the 15 
regulation of signaling receptor activity biological processes (GO). In addition, it was found to 16 
have an action in MAPK1/MAPK3 signaling by the Reactome pathway analysis. The NRG1 17 
gene was found to play a significant role in the downregulation of ERBB2 signaling, 18 
MAPK1/MAPK3 signaling, and in PI3K events in ERBB2 signaling in the Reactome pathway 19 
analysis. In terms of the biological process (GO), they were found to be involved in the positive 20 
regulation of peptidyl-tyrosine phosphorylation and the regulation of signaling receptor activity. 21 
Finally, from the search against SMART protein domains, they were also found to play a role in 22 
the epidermal growth factor-like domain. EREG was also found to possess all the characteristics 23 
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of the NRG1 gene, and in addition, they were also found to be involved in mitogen and 1 
angiogenesis. These findings were well supported in several previous studies on breast cancer-2 
causing genes and pathways (Arora et al. 2016; Coticchia et al. 2009; Sudhakar et al. 2016; 3 
Thirumal Kumar and George Priya Doss 2016a). Thus, this study suggests that the IL6, CXCL8, 4 
VEGF-C, NRG1, and EREG genes might be suitable biomarkers in the treatment of CLBC. 5 
 6 
Conclusion 7 
A comprehensive bioinformatics approach was performed to identify the pathways and genes 8 
that were significantly enriched between the SUM159 CLBC cell line expressing microRNA-203 9 
and control cells. The microarray data were obtained from the GEO database with ID GSE50697. 10 
A total of 165 genes were found to be differentially expressed. Based on the logFC values, 69 11 
genes were found to be upregulated, and 64 genes were classified as downregulated. The 12 
upregulated genes were prioritized for GO and refined GO analyses using the built-in packages 13 
of Chipster and MetaCore, respectively. Pathway analysis identified 193 pathways, of which the 14 
inflammatory IL-13 signaling pathway was found to be the most significantly enriched. Five 15 
upregulated genes (IL6, CXCL8, VEGF-C, NRG1, and EREG) were mapped as hubs, indicating 16 
that they might play crucial roles in CLBC. High levels of IL6, CXCL8, and EREG and low 17 
levels of VEGFC and NRG1 were found to be related to high survival rates through survival 18 
analysis. Finally, through box plot analysis, the expression levels of IL6 and NRG1 were found to 19 
be significantly higher than those of the other genes. This study suggests that the five genes IL6, 20 
CXCL8, VEGF-C, NRG1, and EREG might be potential biomarkers for CLBC. 21 
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Figure Legends 2 
 3 
Figure 1. Gene interaction network of significant genes obtained via the STRING 4 
database. 5 
Figure 2. Gene interaction network of only the significantly upregulated genes 6 
obtained via the STRING database. 7 
Figure 3A-D. (A) Top 10 pathway profiles; (B) top 10 GO processes; (C) top 10 8 
process networks; (D) top 10 diseases according to biomarkers. 9 
Figure 4A. Pathway of the immune response-related IL-13 signaling via JAK-10 
STAT. 11 
Figure 4B. Pathway of G protein-coupled receptor signaling in lung cancer. 12 
Figure 4C. Pathway of cell adhesion ECM remodeling with a top-scored map. 13 
Figure 5. Kaplan–Meier overall survival and box plot analysis of the hub genes 14 
expressed in the SUM159 breast cancer cell line: (A and B) IL6 gene, (C and D) 15 
CXCL8 gene, (E and F) VEGFC gene, (G and H) NRG1 gene, and (I and J) EREG 16 
gene. 17 
Figure 6. Network visualization showing the correlation between the identified 18 
hub genes (IL6, CXCL8, VEGF-C, NRG1, and EREG). The network was 19 
visualized using the online STRING server. Color codes: cyan – positive 20 
18 
 
regulation of peptidyl-tyrosine phosphorylation, brown – regulation of signaling 1 
receptor activity, dark green – downregulation of ERBB2 signaling, yellow – 2 
MAPK1/MAPK3 signaling, red – mitogen, violet – angiogenesis, light green – 3 
epidermal growth factor-like domain. 4 
 5 
Table Legends 6 
 7 
Table 1. Top 10 maps identified from the refined GO study using MetaCore and 8 
the list of genes mapped from the network objects from active data. 9 
Table 2. Top 10 processes identified from the refined GO using MetaCore study 10 
and the list of genes mapped from the network objects from active data. 11 
Table 3. Top 10 networks identified from the refined GO using MetaCore study 12 
and the list of genes mapped from the network objects from active data. 13 
Table 4. List of top 3 networks and their processes identified using the refined GO 14 
process. 15 
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 1 
# Maps  Network Objects fromAcve Data
1 Immune response_IL-13 signaling via JAK-STAT IL13RA2, FOXJ1, SCCA-2, iNOS, SCCA-1
2 G protein-coupled receptors signaling in lung cancer CNR1, Galpha(i)-specific cannabis GPSRs, VIP receptor 1, IL-8, HB-EGF(mature), HB-EGF
3 Cell adhesion_ECM remodeling Collagen III, IL-8, HB-EGF, Versican, TIMP3
4 Maturation and migration of dendritic cells in skin sensitization IL-6, IL-8, ASK1 (MAP3K5), MHC class II alpha chain
5 Multiple myeloma (general schema) IL-6, WHSC1, DKK1
6 Neuroendocrine transdifferentiation in Prostate Cancer IL-6, IL-8, HB-EGF, PTHrP
7 PDE4 regulation of cyto/chemokine expression in inflammatory skin diseases IL-6, IL-8, Adenylate cyclase, iNOS
8 Role of fibroblasts in the sensitization phase of allergic contact dermatitis IL-6, Collagen III, IL-8
9 Immune response_MIF-mediated glucocorticoid regulation IL-6, IL-8, iNOS
10 ERBB family and HGF signaling in gastric cancer Neuregulin 1, IL-8, HB-EGF, Epiregulin
# Processes  Network Objects fromAcve Data
1 second-messenger-mediated signaling
CCL20, Olfactory receptor, GPR110, Galpha(s)-specific class A orphan/other GPCRs, GPR64, IL-
8, AMPK alpha 1 subunit, AMPK alpha subunit, GPR65, NF-AT3(NFATC4), NF-AT, ATP1A2, 
ATP1alpha subunit, OA1, Adenylate cyclase type II, Adenylate cyclase, G-protein gamma, 
iNOS, Ankyrin-B, PTHrP
2 anatomical structure development
FHL2, LUZP1, GPR18, ACTL8, CNR1, Galpha(i)-specific cannabis GPSRs, RABGAP1L, RBG10, 
Keratin HB6, Gamma crystallin C, Keratin 17, LPP3, PPAP2, ECM2/SC1, IL-6, Olfactory 
receptor, GPR110, Neuregulin 1, Dynein, axonemal, heavy chains, Galpha(s)-specific class A 
orphan/other GPCRs, HMGA2, TRIM15, G3ST1, Collagen III, NPAS2, WHSC1, DLG5(P-dlg), 
MAZR, MPV17L, Podoplanin, COX VIIb-1, COX VIIb, PCDH17, MSI2, LAMB3, ITGB8, MST4, 
TNNT1, Troponin T, skeletal, Cdc42 subfamily, Rho GTPase, IL-8, BACE2, DKK1, HB-EGF, 
COL9A3, Dynamin-3, Dynamin, GPR65, MAP7(EMAP115), 5'-NTD, FGF13, FOXJ1, PHLDA1, 
KCRU, SGK1, Myomesin 2, Alpha 1-antitrypsin, ZNF420, PTPR-sigma, HSD11B1, RGS2, Formin, 
NF-AT3(NFATC4), NF-AT, INTU, FGF1, TACC2, ATP1alpha subunit, MKP-3, ANGPTL6, 
Aggrecanase-2, Adenylate cyclase, SNF2L1, K(+) channel, subfamily J, Kir1.1, E2F7, Epiregulin, 
MHC class II alpha chain, TMEFF2, G-protein gamma, KRT81, HIC1, HIC1/2, Versican, Versican 
proteoglycan, C4orf34, iNOS, VEGF-C, TIMP3, SIX6, CHST2, Carbohydrate sulfotransferases, 
NEBL, UMODL1, OTX2, Ankyrin-B, IBP5, IBP, PTHrP, CUTL2
3 multicellular organism development
FHL2, LUZP1, GPR18, CNR1, Galpha(i)-specific cannabis GPSRs, RABGAP1L, RBG10, Keratin 
HB6, Gamma crystallin C, Keratin 17, LPP3, PPAP2, ECM2/SC1, IL-6, Olfactory receptor, 
GPR110, Neuregulin 1, Dynein, axonemal, heavy chains, Galpha(s)-specific class A 
orphan/other GPCRs, HMGA2, TRIM15, G3ST1, Collagen III, NPAS2, WHSC1, DLG5(P-dlg), 
MAZR, MPV17L, Podoplanin, COX VIIb-1, COX VIIb, PCDH17, LAMB3, ITGB8, MST4, Cdc42 
subfamily, Rho GTPase, IL-8, BACE2, DKK1, HB-EGF, COL9A3, Dynamin-3, Dynamin, GPR65, 
MAP7(EMAP115), 5'-NTD, FGF13, FOXJ1, PHLDA1, KCRU, SGK1, Myomesin 2, Alpha 1-
antitrypsin, ZNF420, PTPR-sigma, HSD11B1, RGS2, Formin, NF-AT3(NFATC4), NF-AT, INTU, 
FGF1, TACC2, ATP1alpha subunit, MKP-3, ANGPTL6, Aggrecanase-2, Adenylate cyclase, 
SNF2L1, K(+) channel, subfamily J, Kir1.1, E2F7, Epiregulin, MHC class II alpha chain, G-
protein gamma, KRT81, HIC1, HIC1/2, Versican, Versican proteoglycan, C4orf34, iNOS, VEGF-
C, TIMP3, SIX6, CHST2, Carbohydrate sulfotransferases, NEBL, UMODL1, OTX2, Ankyrin-B, 
IBP5, IBP, PTHrP, CUTL2
4 regulation of multicellular organismal process
CCL20, GPR18, CNR1, Galpha(i)-specific cannabis GPSRs, Keratin 17, LPP3, PPAP2, IL-6, 
Olfactory receptor, Neuregulin 1, Galpha(s)-specific class A orphan/other GPCRs, HMGA2, 
TRIM15, Collagen III, WHSC1, DLG5(P-dlg), MAZR, Podoplanin, AMIGO2, ITGB8, KCNMB4, 
LCAT, TNNT1, Troponin T, skeletal, Cdc42 subfamily, Rho GTPase, IL-8, DKK1, AMPK alpha 1 
subunit, AMPK alpha subunit, HB-EGF, Dynamin-3, Dynamin, FGF13, FOXJ1, LLIR, SGK1, PTPR-
sigma, RGS2, NF-AT3(NFATC4), NF-AT, INTU, DOCK4, FGF1, ATP1A2, ATP1alpha subunit, 
RNF125, Sclerostin, MKP-3, Aggrecanase-2, Adenylate cyclase, K(+) channel, subfamily J, 
Epiregulin, HLA-DQA1, MHC class II alpha chain, HLA-DQA, G-protein gamma, KIAA0748, 
iNOS, VEGF-C, SCCA-1, UMODL1, OTX2, Ankyrin-B, IBP5, IBP, PTHrP, CUTL2
5 cellular response to hormone stimulus
FHL2, PPAP2, IL-6, Olfactory receptor, Galpha(s)-specific class A orphan/other GPCRs, 
ATP6V0A, ATP6V0A2, Cdc42 subfamily, Rho GTPase, AMPK alpha 1 subunit, AMPK alpha 
subunit, FOXJ1, SGK1, HSD11B1, p67-phox, ATP1A2, ATP1alpha subunit, Sclerostin, 
Adenylate cyclase type II, Adenylate cyclase, HLA-DQA1, MHC class II alpha chain, HLA-DQA, 
G-protein gamma 11, G-protein gamma, ATP6V1C, ATP6V1C1, UMODL1, IBP
6 developmental process
FHL2, LUZP1, GPR18, ACTL8, CNR1, Galpha(i)-specific cannabis GPSRs, STYK1, RABGAP1L, 
RBG10, Keratin HB6, Gamma crystallin C, Keratin 17, LPP3, PPAP2, ECM2/SC1, IL-6, Olfactory 
receptor, GPR110, Neuregulin 1, Dynein, axonemal, heavy chains, Galpha(s)-specific class A 
orphan/other GPCRs, HMGA2, TRIM15, G3ST1, Collagen III, NPAS2, WHSC1, DLG5(P-dlg), 
MAZR, MPV17L, Podoplanin, COX VIIb-1, COX VIIb, PCDH17, MSI2, LAMB3, ITGB8, MST4, 
TNNT1, Troponin T, skeletal, Cdc42 subfamily, Rho GTPase, IL-8, BACE2, DKK1, HB-EGF, 
COL9A3, Dynamin-3, Dynamin, GPR65, MAP7(EMAP115), 5'-NTD, FGF13, FOXJ1, PHLDA1, 
KCRU, SGK1, Myomesin 2, Alpha 1-antitrypsin, ZNF420, PTPR-sigma, HSD11B1, RGS2, Formin, 
NF-AT3(NFATC4), NF-AT, INTU, FGF1, p67-phox, TACC2, ATP1alpha subunit, MKP-3, 
ANGPTL6, Aggrecanase-2, Adenylate cyclase, SNF2L1, K(+) channel, subfamily J, Kir1.1, E2F7, 
Epiregulin, MHC class II alpha chain, TMEFF2, G-protein gamma, KRT81, HIC1, HIC1/2, 
Versican, Versican proteoglycan, C4orf34, iNOS, VEGF-C, TIMP3, SIX6, KYNU, CHST2, 
Carbohydrate sulfotransferases, NEBL, UMODL1, OTX2, Ankyrin-B, IBP5, IBP, PTHrP, CUTL2
7 response to hormone
FHL2, PPAP2, IL-6, Olfactory receptor, Neuregulin 1, Galpha(s)-specific class A orphan/other 
GPCRs, ATP6V0A, ATP6V0A2, LCAT, Cdc42 subfamily, Rho GTPase, AMPK alpha 1 subunit, 
AMPK alpha subunit, FOXJ1, SGK1, Alpha 1-antitrypsin, MTAP, HSD11B1, p67-phox, ATP1A2, 
ATP1alpha subunit, Sclerostin, Adenylate cyclase type II, Adenylate cyclase, K(+) channel, 
subfamily J, Epiregulin, HLA-DQA1, MHC class II alpha chain, HLA-DQA, G-protein gamma 11, 
G-protein gamma, ATP6V1C, ATP6V1C1, iNOS, TIMP3, UMODL1, IBP5, IBP
8 regulation of cellular component movement
CCL20, GPR18, LPP3, PPAP2, IL-6, Neuregulin 1, Dynein, axonemal, heavy chains, Galpha(s)-
specific class A orphan/other GPCRs, Collagen III, DLG5(P-dlg), MAZR, Podoplanin, MST4, 
Cdc42 subfamily, Rho GTPase, IL-8, HB-EGF, FGF13, SGK1, DOCK4, FGF1, ATP1A2, ATP1alpha 
subunit, K(+) channel, subfamily J, Epiregulin, TMEFF2, VEGF-C, Carbohydrate 
sulfotransferases, SCCA-1, Ankyrin-B, IBP5, IBP
9 regulation of response to stimulus
CCL20, FHL2, GPR18, CNR1, Galpha(i)-specific cannabis GPSRs, STYK1, NUP210, SLC39A10, 
LPP3, PPAP2, IL-6, Olfactory receptor, Neuregulin 1, Galpha(s)-specific class A orphan/other 
GPCRs, HMGA2, PARG1, TRIM15, Collagen III, NPAS2, WHSC1, DLG5(P-dlg), MPV17L, BCAP, 
SNX25, Podoplanin, IL13RA2, MST4, TNNT1, Troponin T, skeletal, WRCH-1, Cdc42 subfamily, 
Rho GTPase, IL-8, Klhl15, DKK1, AMPK alpha 1 subunit, AMPK alpha subunit, HB-EGF, 
Dynamin, GPR65, 5'-NTD, FGF13, FOXJ1, LLIR, SCCA-2, PTPR-sigma, RGS2, NF-AT3(NFATC4), 
NF-AT, INTU, FGF1, C1r, ATP1A2, ATP1alpha subunit, RNF125, Sclerostin, MKP-3, LASP1, OA1, 
ASK1 (MAP3K5), Adenylate cyclase, MUCL1, Epiregulin, HLA-DQA1, MHC class II alpha chain, 
HLA-DQA, G-protein gamma, ATP6V1C, HIC1, HIC1/2, KIAA0748, RSG5, iNOS, VEGF-C, TIMP3, 
SCCA-1, OTX2, Mucin 12, IBP5, IBP, PTHrP, CUTL2
10 anatomical structure morphogenesis
FHL2, LUZP1, Keratin 17, LPP3, PPAP2, ECM2/SC1, IL-6, Olfactory receptor, Neuregulin 1, 
Dynein, axonemal, heavy chains, Galpha(s)-specific class A orphan/other GPCRs, HMGA2, 
TRIM15, Collagen III, WHSC1, DLG5(P-dlg), Podoplanin, LAMB3, ITGB8, MST4, TNNT1, 
Troponin T, skeletal, Cdc42 subfamily, Rho GTPase, IL-8, DKK1, HB-EGF, Dynamin, 
MAP7(EMAP115), FOXJ1, SGK1, Myomesin 2, Formin, NF-AT3(NFATC4), NF-AT, INTU, FGF1, 
ANGPTL6, Aggrecanase-2, Adenylate cyclase, E2F7, Epiregulin, TMEFF2, G-protein gamma, 
VEGF-C, SIX6, NEBL, OTX2, Ankyrin-B, IBP5, IBP, PTHrP
# Networks  Network Objects fromAcve Data
1 Inflammation_IL-13 signaling pathway IL13RA2, FOXJ1, SCCA-2, Adenylate cyclase type II, iNOS, SCCA-1
2 Cell adhesion_Cell-matrix interactions ECM2/SC1, Collagen III, LAMB3, COL9A3, ITGA9, Aggrecanase-2, Versican, TIMP3
3 Inflammation_Histamine signaling CCL20, IL-6, IL-8, p67-phox, Adenylate cyclase type II, Adenylate cyclase, iNOS
4 Immune response_Innate immune response to RNA viral infection CCL20, IL-6, IL-8, iNOS
5 Signal transduction_ESR1-membrane pathway Neuregulin 1, HB-EGF, Adenylate cyclase type II, Adenylate cyclase
6 Inflammation_MIF signaling IL-6, IL-8, Adenylate cyclase type II, Adenylate cyclase, iNOS
7 Immune response_Th17-derived cytokines CCL20, IL-6, IL-8, iNOS
8 Inflammation_Neutrophil activation IL-6, IL-8, p67-phox, Adenylate cyclase type II, Adenylate cyclase, iNOS
9 Inflammation_IL-4 signaling IL-6, IL13RA2, IL-8, HLA-DQA1
10 Proteolysis_Connective tissue degradation Collagen III, Alpha 1-antitrypsin, Aggrecanase-2, TIMP3
No Network name Processes
1
IL‑8, IL‑6, VEGF‑C, Neuregulin 1, Epiregulin
regulation of cell proliferation (90.0%), positive regulation of intracellular 
signal transduction (72.0%), positive regulation of protein metabolic process 
(80.0%), positive regulation of multicellular organismal process (82.0%), 
response to hormone (74.0%)
2
WHSC1, Alpha 1‑antitrypsin, WRCH‑1, Tetraspanin‑7, GPR65
response to peptide (40.0%), response to organic cyclic compound (48.9%), 
response to peptide hormone (35.6%), response to organonitrogen compound 
(46.7%), intracellular signal transduction (51.1%)
3
BCAP, RNF125, ANKRD18B, SCCA‑1, LAMB3
positive regulation of CD8‑positive, alpha‑beta T cell proliferation (52.1%), 
regulation of CD8‑positive, alpha‑beta T cell proliferation (52.1%), antigen 
processing and presentation of endogenous peptide antigen via MHC class I via 
ER pathway, TAP‑independent (50.0%), positive regulation of tolerance 
induction to nonself antigen (47.9%), regulation of tolerance induction to 
nonself antigen (47.9%)
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